Feature

Ernexa moving a scalable, off-the-shelf cell therapy platform toward the clinic

Ernexa Therapeutics (NASDAQ: ERNA) is developing engineered cell therapies designed to modulate the immune system and address significant unmet needs in cancer and autoimmune disease. The company aims to advance its...

November 3, 2026

Feature

Inventiva targeting MASH at its biological roots

Inventiva (Euronext Paris and Nasdaq: IVA) is advancing development of an oral treatment for metabolic dysfunction-associated steatohepatitis (MASH) with its investigational next-generation pan-peroxisome proliferator...

October 20, 2026

Feature

AIM advancing immunology solutions for globally important diseases

AIM ImmunoTech (NYSE American: AIM) is developing Ampligen, an immune modulator with potential applications across oncology, immune disorders, and viral diseases. The company is currently focused on developing Ampligen...

October 6, 2026

Feature

Akebia challenging the status quo in kidney disease

Akebia Therapeutics (NASDAQ: AKBA) is advancing the Nobel Prize-winning science behind hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) through its commercial product, Vafseo, an oral therapy designed...

September 29, 2026

NEWS

Just a few of the companies we’ve highlighted along the way

Giving healthcare companies and their stories the exposure they deserve.

Ernexa moving a scalable, off-the-shelf cell therapy platform toward the clinic

Inventiva targeting MASH at its biological roots

AIM advancing immunology solutions for globally important diseases

Akebia challenging the status quo in kidney disease

NEWS

Analysts see CMS’ 2027 Final Rule favorable to Profound Medical’s MRI-guided, incision-free TULSA procedure

Profound’s TULSA-PRO delivers first MRI-guided prostate ablation treatment in New Zealand

Lucid announces publication of 12,000-patient real-world EsoGuard study

FDA clears Pasithea’s IND application for Phase 2 trial of PAS-004 in cNF

Specific announces oversubscribed $35 million Series A financing to advance gene-editing therapy for ALS

HeartBeam reveals positive results of heart attack assessment study at TCT

NeuroSense strengthens PrimeC Canadian ALS submission

Allarity secures first commercial agreement under new CLIA laboratory services strategy

Profound and Cook in potentially transformational iMRI partnership for TULSA-PRO

Just a few of the companies we’ve highlighted along the way

Subscribe